India’s Arcolab Completes Buy Of Australia’s Ascent
This article was originally published in PharmAsia News
Executive Summary
Strides Arcolab of India says it has completed its purchase of a majority stake in Ascent Pharmahealth of Australia. The purchase of a 50.1 percent interest in the firm would make Strides the fourth largest maker of generic pharmaceuticals in Australia when the deal is certified in September. The Indian firm already had an agreement with Genepharm to transfer its Australia and Asia businesses to Ascent. Shareholders have cleared a name change of Genepharm Australasia to Ascent Pharmahealth. (Click here for more